Published in Blood on July 09, 2008
Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol (2012) 2.36
Heparan sulfate, an endogenous TLR4 agonist, promotes acute GVHD after allogeneic stem cell transplantation. Blood (2012) 1.71
PKCtheta is required for alloreactivity and GVHD but not for immune responses toward leukemia and infection in mice. J Clin Invest (2009) 1.37
Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality. Blood (2009) 1.35
TLR signals promote IL-6/IL-17-dependent transplant rejection. J Immunol (2009) 1.26
Antibody to the dendritic cell surface activation antigen CD83 prevents acute graft-versus-host disease. J Exp Med (2009) 1.08
Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. Immunotherapy (2009) 1.07
HDAC inhibition and graft versus host disease. Mol Med (2011) 1.02
Effective posttransplant antitumor immunity is associated with TLR-stimulating nucleic acid-immunoglobulin complexes in humans. J Clin Invest (2011) 1.01
GVHD-associated, inflammasome-mediated loss of function in adoptively transferred myeloid-derived suppressor cells. Blood (2015) 0.97
The role of pattern-recognition receptors in graft-versus-host disease and graft-versus-leukemia after allogeneic stem cell transplantation. Front Immunol (2014) 0.86
Blood dendritic cells suppress NK cell function and increase the risk of leukemia relapse after hematopoietic cell transplantation. Biol Blood Marrow Transplant (2010) 0.85
The biology of allogeneic hematopoietic cell resistance. Biol Blood Marrow Transplant (2009) 0.85
The role of bacteria and pattern recognition receptors in GVHD. Int J Inflam (2010) 0.83
Donor TLR9 gene tagSNPs influence susceptibility to aGVHD and CMV reactivation in the allo-HSCT setting without polymorphisms in the TLR4 and NOD2 genes. Bone Marrow Transplant (2013) 0.82
Innate immunity and transplantation tolerance: the potential role of TLRs/NLRs in GVHD. Korean J Hematol (2011) 0.82
Various forms of tissue damage and danger signals following hematopoietic stem-cell transplantation. Front Immunol (2015) 0.81
Expansion of donor-reactive host T cells in primary graft failure after allogeneic hematopoietic SCT following reduced-intensity conditioning. Bone Marrow Transplant (2013) 0.81
GVHD prevention: an ounce is better than a pound. Biol Blood Marrow Transplant (2012) 0.79
Thyroid antigens, not central tolerance, control responses to immunization in BALB/c versus C57BL/6 mice. Thyroid (2009) 0.79
Innate immune activation by tissue injury and cell death in the setting of hematopoietic stem cell transplantation. Front Immunol (2015) 0.78
Role of Toll-Like Receptor Signaling in the Pathogenesis of Graft-versus-Host Diseases. Int J Mol Sci (2016) 0.77
Serum miR-29a Is Upregulated in Acute Graft-versus-Host Disease and Activates Dendritic Cells through TLR Binding. J Immunol (2017) 0.77
Highlights of the First International "Immunotherapy in Pediatric Oncology: Progress and Challenges" Meeting. J Pediatr Hematol Oncol (2009) 0.77
Danger Signals and Graft-versus-host Disease: Current Understanding and Future Perspectives. Front Immunol (2016) 0.77
MyD88 in donor bone marrow cells is critical for protection from acute intestinal graft-vs.-host disease. Mucosal Immunol (2015) 0.77
Possible implication of bacterial infection in acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Front Oncol (2014) 0.76
Donor dendritic cells dance the do-si-do in allogeneic transplantation. Blood (2008) 0.75
Targeting deacetylases to improve outcomes after allogeneic bone marrow transplantation. Trans Am Clin Climatol Assoc (2013) 0.75
Combined nifuroxazide and SAT05f therapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation. Cell Death Dis (2016) 0.75
TLR-Induced Murine Dendritic Cell (DC) Activation Requires DC-Intrinsic Complement. J Immunol (2017) 0.75
TLR/MyD88-mediated Innate Immunity in Intestinal Graft-versus-Host Disease. Immune Netw (2017) 0.75
Innate immune recognition. Annu Rev Immunol (2001) 26.65
Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol (2002) 13.10
Toll-like receptors in innate immunity. Int Immunol (2005) 12.24
CpG motifs in bacterial DNA trigger direct B-cell activation. Nature (1995) 12.24
CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol (2001) 9.19
Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med (2001) 8.60
Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol (2002) 7.60
Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science (1999) 6.02
Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci U S A (2001) 5.02
Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4. Nature (2002) 4.81
The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors. Nature (2002) 4.15
Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med (1997) 4.12
CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med (1997) 4.06
Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med (2002) 3.94
Antiviral signaling through pattern recognition receptors. J Biochem (2006) 3.84
Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol (2001) 3.64
Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol (2001) 3.34
Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease. Nat Med (2004) 3.17
Toll-like receptor ligands directly promote activated CD4+ T cell survival. J Immunol (2004) 2.79
Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol (1996) 2.74
Development of TLR9 agonists for cancer therapy. J Clin Invest (2007) 2.64
Innate immune recognition of, and regulation by, DNA. Trends Immunol (2006) 2.57
Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci U S A (1997) 2.35
Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity. Immunol Rev (2007) 2.22
Preterminal host dendritic cells in irradiated mice prime CD8+ T cell-mediated acute graft-versus-host disease. J Clin Invest (2002) 1.98
An inflammatory checkpoint regulates recruitment of graft-versus-host reactive T cells to peripheral tissues. J Exp Med (2006) 1.94
Preformed antibody, not primed T cells, is the initial and major barrier to bone marrow engraftment in allosensitized recipients. Blood (2006) 1.92
Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J Immunol (2004) 1.91
CpG motifs: the active ingredient in bacterial extracts? Nat Med (2003) 1.89
Bacterial CpG DNA activates immune cells to signal infectious danger. Adv Immunol (1999) 1.75
The role of CpG motifs in innate immunity. Curr Opin Immunol (2000) 1.74
TLR7 and TLR8 as targets in cancer therapy. Oncogene (2008) 1.72
Bacterial CpG-DNA activates dendritic cells in vivo: T helper cell-independent cytotoxic T cell responses to soluble proteins. Eur J Immunol (2000) 1.58
APCs in the liver and spleen recruit activated allogeneic CD8+ T cells to elicit hepatic graft-versus-host disease. J Immunol (2002) 1.52
Toll-like receptors and innate immunity in B-cell activation and antibody responses. Curr Opin Immunol (2007) 1.37
First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer. Clin Cancer Res (2007) 1.25
The antiviral activity of Toll-like receptor 7 and 7/8 agonists. Drug News Perspect (2008) 1.23
Synthetic agonists of Toll-like receptors 7, 8 and 9. Biochem Soc Trans (2007) 1.20
Dendritic cells (DC) activated by CpG DNA ex vivo are potent inducers of host resistance to an intracellular pathogen that is independent of IL-12 derived from the immunizing DC. J Immunol (2004) 1.18
In vivo manipulation of dendritic cells to induce therapeutic immunity. Blood (2002) 1.16
Dendritic cell maturation and subsequent enhanced T-cell stimulation induced with the novel synthetic immune response modifier R-848. Cell Immunol (1999) 1.16
CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells. J Immunol (2005) 1.15
Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA. Curr Top Microbiol Immunol (2006) 1.11
The antitumoral mode of action of imiquimod and other imidazoquinolines. Curr Med Chem (2007) 1.09
Immune recognition of foreign DNA: a cure for bioterrorism? Immunity (1999) 1.05
Innate immunity for biodefense: a strategy whose time has come. J Allergy Clin Immunol (2005) 1.04
Administration of a dual toll-like receptor 7 and toll-like receptor 8 agonist protects against influenza in rats. Antiviral Res (2006) 1.04
Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor. Blood (1998) 0.95
Immune mechanisms and therapeutic potential of CpG oligodeoxynucleotides. Int Rev Immunol (2006) 0.92
TLR9 agonists as adjuvants for prophylactic and therapeutic vaccines. Curr Opin Mol Ther (2007) 0.92
TLR7 imidazoquinoline ligand 3M-019 is a potent adjuvant for pure protein prototype vaccines. Cancer Immunol Immunother (2006) 0.87
Restoring function in exhausted CD8 T cells during chronic viral infection. Nature (2005) 28.04
The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol (2004) 26.12
Toll-like receptors. Annu Rev Immunol (2001) 26.06
Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med (2006) 24.38
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol (2010) 24.08
Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature (2006) 22.65
Pattern recognition receptors and inflammation. Cell (2010) 21.05
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol (2008) 19.24
IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat Immunol (2005) 18.32
Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science (2003) 17.57
Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science (2004) 16.26
5'-Triphosphate RNA is the ligand for RIG-I. Science (2006) 15.78
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science (2004) 14.80
The B7 family revisited. Annu Rev Immunol (2005) 13.51
Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol (2002) 13.10
Toll-like receptors in innate immunity. Int Immunol (2005) 12.24
Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. Nature (2008) 11.39
Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity (2011) 11.15
Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature (2006) 9.77
Innate immune recognition of viral infection. Nat Immunol (2006) 9.59
Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature (2004) 9.40
Cell type-specific involvement of RIG-I in antiviral response. Immunity (2005) 9.37
Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J Immunol (2005) 9.17
TLR signaling pathways. Semin Immunol (2004) 9.08
Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J Exp Med (2008) 9.00
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity (2007) 8.94
TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature (2007) 8.87
Impacts of the Cretaceous Terrestrial Revolution and KPg extinction on mammal diversification. Science (2011) 8.23
TLR signaling. Semin Immunol (2007) 8.16
A Toll-like receptor-independent antiviral response induced by double-stranded B-form DNA. Nat Immunol (2005) 7.94
TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta. Nat Immunol (2008) 7.87
ER stress triggers apoptosis by activating BH3-only protein Bim. Cell (2007) 7.50
Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2. J Exp Med (2003) 7.38
Two Beclin 1-binding proteins, Atg14L and Rubicon, reciprocally regulate autophagy at different stages. Nat Cell Biol (2009) 7.35
Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood (2005) 7.28
Toll-like receptor 9-mediated recognition of Herpes simplex virus-2 by plasmacytoid dendritic cells. J Exp Med (2003) 7.26
Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat Med (2007) 7.25
Distinct RIG-I and MDA5 signaling by RNA viruses in innate immunity. J Virol (2007) 7.18
Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med (2005) 7.18
Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood (2004) 7.09
Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling. J Immunol (2002) 7.07
Innate immunity to virus infection. Immunol Rev (2009) 7.04
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med (2009) 6.80
Involvement of linear polyubiquitylation of NEMO in NF-kappaB activation. Nat Cell Biol (2009) 6.62
Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med (2007) 6.52
Targeted disruption of the Chop gene delays endoplasmic reticulum stress-mediated diabetes. J Clin Invest (2002) 6.48
A molecular phylogeny for bats illuminates biogeography and the fossil record. Science (2005) 6.47
Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology (2004) 6.47
Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood (2007) 6.45
28-way vertebrate alignment and conservation track in the UCSC Genome Browser. Genome Res (2007) 6.42
TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. Nature (2008) 6.40
Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell (2008) 6.37
Placental mammal diversification and the Cretaceous-Tertiary boundary. Proc Natl Acad Sci U S A (2003) 6.29
Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med (2004) 6.26
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med (2010) 6.24
Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat Immunol (2005) 6.13
The PD-1 pathway in tolerance and autoimmunity. Immunol Rev (2010) 5.99
Toll-like receptors on hematopoietic progenitor cells stimulate innate immune system replenishment. Immunity (2006) 5.98
Toll-like receptor and RIG-I-like receptor signaling. Ann N Y Acad Sci (2008) 5.95
The costimulatory molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular T helper cells and TH-17 cells. Nat Immunol (2008) 5.92
Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med (2006) 5.88
Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood (2010) 5.79
Pathogen recognition by the innate immune system. Int Rev Immunol (2011) 5.76
The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood (2002) 5.72
Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat Immunol (2004) 5.71
Regulation of innate antiviral defenses through a shared repressor domain in RIG-I and LGP2. Proc Natl Acad Sci U S A (2006) 5.70
Recognition of 5' triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus. Immunity (2009) 5.70
Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med (2006) 5.63
Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci U S A (2004) 5.58
TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes Dev (2005) 5.56
Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J Immunol (2002) 5.48
Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol (2002) 5.41
IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells. J Immunol (2007) 5.31
Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett (2003) 5.27
The roles of TLRs, RLRs and NLRs in pathogen recognition. Int Immunol (2009) 5.21
Regulation of Legionella phagosome maturation and infection through flagellin and host Ipaf. J Biol Chem (2006) 5.11
Regulation of humoral and cellular gut immunity by lamina propria dendritic cells expressing Toll-like receptor 5. Nat Immunol (2008) 5.10
Essential role of IPS-1 in innate immune responses against RNA viruses. J Exp Med (2006) 5.01
TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway. Nat Immunol (2003) 4.94
Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med (2005) 4.92
Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway. Nat Immunol (2005) 4.91
RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med (2005) 4.85
The RNA helicase Lgp2 inhibits TLR-independent sensing of viral replication by retinoic acid-inducible gene-I. J Immunol (2005) 4.83
Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4. Nature (2002) 4.81
PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc Natl Acad Sci U S A (2004) 4.75
Toll-like receptor 2 controls expansion and function of regulatory T cells. J Clin Invest (2006) 4.72
Initial sequence and comparative analysis of the cat genome. Genome Res (2007) 4.67
The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection. Nat Immunol (2010) 4.66
Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest (2004) 4.65